Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Novo Nordisk hiked annual profit guidance on Wednesday, as the pharmaceutical group revealed its blockbuster weight-loss drugs performed better than expected in the first three months of the year.
- The Danish drugmaker said first-quarter sales jumped 32% on a constant currency basis to reach 96.8 billion Danish kroner ($15.2 billion), soaring above an analyst consensus of 71.3 billion kroner compiled by FactSet.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Novo Nordisk hiked annual profit guidance on Wednesday, as the pharmaceutical group revealed its blockbuster weight-loss drugs performed better than expected in the first three months of the year.
The Danish drugmaker said first-quarter sales jumped 32% on a constant currency basis to reach 96.8 billion Danish kroner ($15.2 billion), soaring above an analyst consensus of 71.3 billion kroner compiled by FactSet. Operating profit surged 65% year-on-year to 59.6 billion kroner, also hugely beating expectations of 31.7 billion kroner.